Emerald Mutual Fund Advisers Trust’s Karyopharm Therapeutics KPTI Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-743	Closed	-$117K	–	231
2021 Q1	$117K	Sell	743 -110,006	-99%	-$23.2M	﹤0.01%	207
2020 Q4	$25.7M	Buy	110,749 +14,115	+15%	+$3.27M	0.89%	38
2020 Q3	$21.2M	Buy	96,634 +27,504	+40%	+$6.73M	0.94%	40
2020 Q2	$19.6M	Buy	69,130 +11,415	+20%	+$3.38M	0.93%	41
2020 Q1	$16.6M	Buy	57,715 +25,306	+78%	+$6.98M	1.04%	31
2019 Q4	$9.32M	Sell	32,409 -63,120	-66%	-$13.7M	0.38%	91
2019 Q3	$13.8M	Buy	95,529 +3,836	+4%	+$520K	0.61%	54
2019 Q2	$8.24M	Sell	91,693 -72	-0.1%	-$5.78K	0.33%	107
2019 Q1	$8.04M	Buy	91,765 +203	+0.2%	+$22.5K	0.32%	114
2018 Q4	$12.9M	Buy	91,562 +48,408	+112%	+$8.17M	0.6%	58
2018 Q3	$11M	Buy	43,154 +11,308	+36%	+$3.13M	0.37%	102
2018 Q2	$8.12M	Buy	+31,846	New	+$7.88M	0.29%	128

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's KPTI Position: Q2 2021 in Review

Emerald Mutual Fund Advisers Trust sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 743 shares — an estimated $117K sold.

Emerald Mutual Fund Advisers Trust first reported a position in KPTI in Q2 2018 and held it in 12 quarters. The position peaked at $25.7M in Q4 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

Emerald Mutual Fund Advisers Trust reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 743 Karyopharm Therapeutics shares in Q2 2021, an estimated $117K.
Emerald Mutual Fund Advisers Trust first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 12 quarters.
Emerald Mutual Fund Advisers Trust's Karyopharm Therapeutics position peaked at $25.7M in Q4 2020.
153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2021, filed 29 Jul 2021.